These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 8763932

  • 1. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS, Fisher LM.
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [Abstract] [Full Text] [Related]

  • 2. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 3. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [Abstract] [Full Text] [Related]

  • 4. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
    Pan XS, Ambler J, Mehtar S, Fisher LM.
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
    [Abstract] [Full Text] [Related]

  • 5. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R, De La Campa AG.
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
    [Abstract] [Full Text] [Related]

  • 6. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [Abstract] [Full Text] [Related]

  • 7. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ, Ambler JE, Fisher LM.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [Abstract] [Full Text] [Related]

  • 8. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY, Trucksis M, Hooper DC.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [Abstract] [Full Text] [Related]

  • 9. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS, Yague G, Fisher LM.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [Abstract] [Full Text] [Related]

  • 10. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM, Grau O, Charron A, Renaudin H, Gruson D, Bébéar C.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [Abstract] [Full Text] [Related]

  • 11. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
    González I, Georgiou M, Alcaide F, Balas D, Liñares J, de la Campa AG.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2792-8. PubMed ID: 9797205
    [Abstract] [Full Text] [Related]

  • 12. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Tankovic J, Perichon B, Duval J, Courvalin P.
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
    [Abstract] [Full Text] [Related]

  • 13. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
    [Abstract] [Full Text] [Related]

  • 14. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [Abstract] [Full Text] [Related]

  • 15. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [Abstract] [Full Text] [Related]

  • 16. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
    Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa AG.
    Microb Drug Resist; 2000 Feb; 6(4):259-67. PubMed ID: 11272253
    [Abstract] [Full Text] [Related]

  • 17. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
    Harding I, Simpson I.
    J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
    [Abstract] [Full Text] [Related]

  • 18. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M, Fukuda H, Yokoi S, Ishihara S, Kawada Y, Deguchi T.
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [Abstract] [Full Text] [Related]

  • 19. Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.
    Bébéar CM, Charron A, Bové JM, Bébéar C, Renaudin J.
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2024-31. PubMed ID: 9687401
    [Abstract] [Full Text] [Related]

  • 20. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E, Beyer R, Cianciotto NP, Noskin GA, Peterson LR.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.